Anbio Presents Rapid, Accessible POCT Diagnostics to WHX Labs Dubai 2026
Posted on 12 Feb 2026
Anbio Biotechnology (Frankfurt, Germany) is participating in WHX Labs Dubai 2026, where the company is showcasing a selection of its latest point-of-care testing (POCT) solutions. Through its exhibition presence, Anbio aims to connect with healthcare professionals, medical device distributors, and patients by offering rapid, accessible, and affordable in vitro diagnostic (IVD) solutions spanning laboratory, wellness, at-home, and point-of-care applications worldwide.
Highlighted at booth S1.F50 is the Anbio FIA Platform, a portfolio of compact, easy-to-use, and cost-effective immunofluorescence (FIA) analyzers designed for rapid point-of-care testing. The platform uses an LED light source within the reader to excite fluorescent dyes, enabling qualitative or quantitative immunochromatographic analysis of analytes in whole blood and urine samples. Supported applications include hormone testing, myocardial disease markers, infectious disease detection, and tumor-associated antigen analysis.
The company is also showcasing its dry chemistry analyzer lineup, including the SHA-100 and SHA-200. The SHA-100 is a compact, portable, single-channel system, while the SHA-200 features a three-channel configuration that delivers up to three times the throughput of a single-channel analyzer. Both systems are designed for ease of use, with touchscreen interfaces that support streamlined, one-step operation, and are compatible with multiple specimen types, including whole blood, serum, and plasma.
Also on display is Anbio’s molecular point-of-care testing platform based on rapid RT-PCR technology. The system automatically monitors PCR amplification of specific gene targets during each cycle and is engineered to complete up to 40 amplification cycles in approximately 15 minutes, according to the company. This fast turnaround supports timely molecular diagnostics at or near the point of care.
Related Links:
Anbio Biotechnology
